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Background/Aims: JX-594 is an oncolytic virus derived from the Wyeth vaccinia strain that causes replication-dependent 
cytolysis and antitumor immunity. Starting with a cross-examination of clinical-trial samples from advanced hepatocellular 
carcinoma patients having high levels of aldosterone and virus amplification in JX-594 treatment, we investigated the association 
between virus amplification and aldosterone in human cancer cell lines. Methods: Cell proliferation was determined by a 
cell-counting-kit-based colorimetric assay, and vaccinia virus quantitation was performed by quantitative polymerase chain 
reaction (qPCR) and a viral plaque assay. Also, the intracellular pH was measured using a pH-sensitive dye. Results: Simultaneous 
treatment with JX-594 and aldosterone significantly increased viral replication in A2780, PC-3, and HepG2 cell lines, but not in 
U2OS cell lines. Furthermore, the aldosterone treatment time altered the JX-594 replication according to the cell line. The JX-594 
replication peaked after 48 and 24 hours of treatment in PC-3 and HepG2 cells, respectively. qPCR showed that JX-594 entry 
across the plasma membrane was increased, however, the changes are not significant by the treatment. This was inhibited by 
treatment with spironolactone (an aldosterone-receptor inhibitor). JX-594 entry was significantly decreased by treatment with 
EIPA [5-(N-ethyl-N-isopropyl)amiloride; a Na
+/H
+-exchange inhibitor], but aldosterone significantly restored JX-594 entry even in 
the presence of EIPA. Intracellular alkalization was observed after aldosterone treatment but was acidified by EIPA treatment. 
Conclusions: Aldosterone stimulates JX-594 amplification via increased virus entry by affecting the H
+ gradient. (Korean J 
Hepatol 2011;17:213-219)
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INTRODUCTION
JX-594 is a targeted, GM-CSF expressing Wyeth strain 
derived oncolytic virus designed to selectively replicate in and 
destroy cancer cells through virus replication-dependent cytolysis 
and induction of anti-tumoral immunity.
1,2 JX-594 replication in 
cancer patients seem to be associated with genetic background of 
cancer cells and patient’s condition as well as the administered 
viral dose. As viral replication in oncolytic virus therapy may be 
essential for therapeutic success, the favorable condition for 
JX-594 replication should be illuminated. In phase 1 hepatoma 
clinical trial of JX-594, viral replication of JX-594 was noted in 
most patients,
3 remarkably more in cancer patients with severe 
ascites and/or peripheral edema. It is assumed that aldosterone 
level is increased in the malignancy patients with ascites which is 
the abnormal accumulation of fluid within the peritoneal cavity 
as a consequence of advance cancer. Sequestration of fluid 
within the abdomen leads to additional fluid retention by the 
kidney due to stimulatory effect on blood pressure hormones, 
notably aldosterone which can cause peripheral edema.214  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Aldosterone is a type of mineralcorticoid hormone to control 
the balance of water and salts in the kidney by keeping sodium in 
and releasing potassium from the body. Aldosterone receptor, 
mineral corticoid receptor (MR), belongs to the nuclear receptor 
family where the ligand diffuses into cells, which interacts with 
the receptor and results in a signal transduction affecting specific 
gene expression in the nucleus. Pathophysiological function of 
aldosterone is well known as a cardiovascular function, but gene 
expression of MR is ubiquitous in most normal organs including 
cancer cells with higher levels in the cortex, amygdala and the 
pituitary gland (5-20 folds of average), cardiomyocytes, uterus 
and lymphocytes (3-5 folds of average) shown in Norvatis 
Research Foundation based BioGPS site.
4 This means that a 
variety of physiological functions other than fluid regulation by 
aldosterone is possible. Accordingly, we addressed the effect of 
aldosterone in JX-594 amplification in vitro in this study.
MATERIALS AND METHODS
Chemicals 
Aldosterone, spirinolactone and 5-(N-Ethyl-N-isopropyl) 
amiloride (EIPA) were purchased from Sigma Aldrich. 2-, 
7-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein 
acetoxymethyl ester (BCECF-AM) from Molecular Probe (Eugene, 
Ore., USA).
Viruses and cell lines
JX-594 was constructed from a Wyeth strain vaccinia virus 
(vv) as described,
5 and JX-963 was constructed from a Western 
Reserve vaccinia virus as described.
6 Both wild type Wyeth 
strain vv and WR strain vv were purchased from ATCC. Human 
hepatocellular carcinoma cell lines (SNU-449 and SNU-475) 
were obtained from Korea Cell Bank (Seoul, Korea) and all other 
cell lines used were obtained from ATCC.
Measurement of cell viability 
Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, 
Inc., Japan) was used in accordance with a company provided 
manual to determine cell growth. In brief, the cells were plated in 
96-well plates 1 day before treatment; pre-incubated cells with 
aldosterone (48 h) or vehicle were washed with PBS, and then 10
μl of CCK-8 was added to the cells and plated for 2-4 hours in a 
humidified incubator (at 37℃, 5% CO2), after which their 
absorbance at 450 nm were measured using ELISA reader 
(ELx808™ Absorbance Microplate Reader, Biotech, Winooski, 
VT, USA). The percentage of viable cells was calculated as the 
ratio of viable cells to total cells absorbance measurements ×100.
In vitro replication and cytopathic effect 
Cell lines were seeded into 6-well plates at 4×10
5 cells/well 
and left overnight. Aldosterone and/or MR inhibitor, spirinolactone, 
were pretreated for different hours (0, 2, 4, 6, 8, 10) before virus 
infection. Virus was then added at an MOI of 1.0 PFU/cell with 
or without aldosterone and/or spironolactone and allowed to 
infect for 2 hours. At the end of the infection, the media was 
changed and plates incubated for 2 hours, 24 hours or 48 hours; 
the cells were then scraped into the media and collected. Cells 
were lysed by 3 rounds of freezing and thawing followed by 
sonication before serial dilutions of the crude viral lysate was 
added to A2780 cells to titer the virus by plaque assay. All 
experiments were run in triplicate. As vv replication was highest 
after pretreatment of aldosterone for 8-10 hour, all study 
otherwise indicated were conducted on this condition.
Measurement of plasma membrane influx of 
vaccinia virus 
As vv replication was highest in PC-3 cell line after 48 hours 
incubation, qPCR quantitation in PC-3 cell line was used to 
determine vv influx. 4×10
5 PC-3 cell/well were seeded in 6 well 
plate 4×10
5 cells/well and incubated overnight. Before virus 
infection, cells were washed with cold PBS and cooled to 4℃ 
and incubated for 1h at 4℃ with indicated (mock, 0.001-10 
MOI) amounts of virus to proceed virus adsorption.
7 Cells are 
washed with cold PBS twice to remove unbound virions and 
further incubate at 37℃ for 30 min with prewarmed complete 
media. Total DNA was isolated using QIAamp DNA Blood mini 
Kit (Qiagen, Hilden, Germany) and quantified using NanoDrop 
ND-1000 spectrophotometer (PeqLab, Erlangen, Germany). The 
copy numbers of genome were quantified using primer set 
specific for 9EL gene (E9L-F1880 5’-GAA CAT TTT TGG 
CAG AGA GAG CC-3’ E9L-R2057 5’-CAA CTC TTA GCC 
GAA GCG TAT GAG-3’ E9L-p1924S-MGB 6’FAM-CAG GCT 
ACC AGT TCA A-MGBNFQ-3’) and 10 ng, 100 ng of DNA 
template using ABI 7300 realtime PCR machine (Applied 
Biosystems, Warrington, UK). To test the effect of aldosterone or 
Na
+/H
+ inhibitor, EIPA, on virus entry, cells were preincubated 
for 2 hours at 37℃ with aldosterone (100 nM) or spirinolactone 
(1 μM) which were diluted in serum free media. Hyun Ju Lee, et al. Aldosterone effect on oncolytic virus in cancer  215
Table 1. Changes in serum cortisol, aldosterone, and JX-594 viral particles in a patient with hepatocellular carcinoma after JX-594 
injection
Days post JX-594 Cortisol (mg/dL) Aldosterone (ng/L) JX-594 (vp/mg DNA)
D0 31.9 1551.2 0
D1 (15 min post JX-594) 21.8 841.7 2,189
D5 28.5 937.8 6,137
D8 28.5 1482.2 11,891
This patient was enrolled into JX-594 Phase 1 hepatoma trial. 
Table 2. Changes in serum cortisol, aldosterone, and vaccina virus particles in normal rabbits (n=4) after JX-594 injection
Dose of vv  Days post vv Cortisol (mg/dL) Aldosterone (ng/L) vv viral particles (vp/mg DNA)
5×10
7pfu D0 0.7±0.2 109.8±14 0
D3 0.9±0.3 165.3±45 0
D5 1.0±0.5 88.6±32 0
D8 0.6±0.5 66.3±36 0
5×10
10pfu D0 0.8±0.4 88.7±22 0
D1 1.0±0.3 496.3±102
* 32
D3 4.0±1.0
* 311.2±88
* 9257
D5 3.4±0.9
* 2123.5±432
* 9323
* P<0.05 (versus D0 level).
Measurement of intracellular pH (pHi)
Intracellular pH was determined using the pH-sensitive dye 
2-,7-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein 
acetoxymethyl ester (BCECF-AM) as described.
8 PC-3 cells 
were prepared for pHi as follows. 5×10
4 cells/well were seeded 
in 24 well plates and incubated overnight. After preincubation 
with 100 μM aldosterone or serum free for 2 hr at 37℃ cells were 
loaded with 2 μM BCECF-AM (Molecular Probes) for 30 
minutes at 37℃ diluted in HBSS buffer. After washing twice 
with HBSS and further incubation with vv for 30 minutes, relative 
fluorescence intensity of treatment groups were measured with 
Infinite F500 Multi-functional Microplate Reader (Tecan Trading 
AG, Mannedorf, Switzerland).
Statistical analysis 
Values are given as mean ± SD (standard deviation). Statistical 
evaluations of data were analyzed using student t test. P-value of 
less than 0.05 was defined as statistically significant.
RESULTS
Among patients with significant malignant ascites who were 
enrolled into phase 1 trial,
3 archival serum (supine position) was 
available in one patient (#303 patient) to measure aldosterone/ 
cortisol level (Table 1). Cortisol level was stable roughly within 
the normal range (5-25 μg/dL), but aldosterone level was 
maintained at around 10 folds higher than the normal range 
(7.5-150 ng/L at supine position) before JX-594 injection. qPCR 
based whole blood viral particles after treatment of JX-594 were 
determined at concomitant time-series. It showed significant 
level on day 5 and further increase on day 8 exhibiting remarkable 
JX-594 replication in this patient. This contrasts with viral 
clearance on day 8 for most patients even when patients show 
virus replication from day 3 (data not shown).
In pilot animal toxicology study, JX-963 with a dosage 1,000 
folds higher than possible therapeutic dose (1.3×10
7 pfu/kg), 
was intravenously injected into normal rabbit, and cortisol level 
and aldosterone level were increased by 3-4 folds and by 4-20 
folds, respectively (Table 2), which may have resulted from 
acute inflammatory change of histological finding in adrenal 
gland (data not shown). In case of #303 patient, the basal level of 216  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
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Figure 1. Effects of aldosterone (ALDO), spironolactone (SPI), and JX-594 on cancer cell lines (n=4). (A) Effects of treatment with 
ALDO (100 nmol) and/or SPI (100 nmol), and JX-594 (100 pfu) infection for 2 hours on A2780 cells (n=6 for each group). (B) 
Effects of pretreatment with ALDO (100 nmol) in JX-594 infection for 2, 4, 6, 8, and 10 hours (n=3 for each group) on virus replication. 
*P<0.05 (ALDO vs. vehicle at each time point). (C) U20S, PC-3, and HepG2 cell lines infected with JX-594 for 2, 24, and 48 hours 
after 10 hours of treatment with ALDO (n=3). (D) Effects of ALDO at 10 and 100 nM on tumor cell growth (n=2). 
*P<0.05.
aldosterone was high which may have affected JX-594 
amplification. The effect of high dose JX-963 in adrenal gland 
stimulation needs further experimentation but was not further 
studied since it was not the primary focus of this study. In this 
study, 5×10
7 pfu injection showed no change in aldosterone, 
cortisol level, histological finding, and in JX-963 amplification. 
Thus, direct effect of aldosterone on JX-594 amplification in 
human cell lines were determined (Fig. 1). As A2780 cancer cell 
line has been used for viral titering during Phase 1 and Phase 
2 JX-594 study, A2780 cell line was initially chosen to determine 
the aldosterone effect on JX-594 amplification. Simultaneous 
treatment of JX-594 and aldosterone (10 nM) significantly 
increased viral replication in A2780 (human ovarian cancer cell 
line), which was completely blocked by co-treatment with MR 
inhibitor, spirinolactone (Fig. 1A). However, treatment of cortisol 
alone did not affect viral replication (data not shown). As 
aldosterone effect may be induced on both genomic and/or 
nongenomic level,
9 we determined whether pretreatment time of 
aldosterone (10 nM) could influence viral replication (Fig. 1B). 
While there was significant increase in JX-594 replication after 
0 (simultaneous treatment) to 6 hours pre-treatment of aldosterone, 
further increase after 8 or 10 hour treatment was observed.
Subsequently, it was determined whether the stimulation of 
JX-594 amplification by aldosterone (10 nM) can vary depending 
on human cancer cell lines. Fig. 1C shows that there were minor 
to major differences in JX-594 replications depending on cell 
types. PC-3 cell showed the highest JX-594 replication after 48 
hour treatment but HepG2 cell showed its peak replication after 
24 hour treatment. Even with different patterns of aldosterone 
effect in different cell lines, the overall stimulatory effect of 
aldosterone in JX-594 amplification in PC3 cell and HepG2 cells 
but not in U2OS cell was observed.
As aldosterone has been reported to proliferate some types of 
cells such as heart cell,
10 peripheral blood monocytes
11 or human 
uterine leiomyoma,
12 it was determined that the stimulation of 
JX-594 amplification may be via cell proliferation by aldosterone. 
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Figure 2. Results of quantitative polymerase chain reaction (qPCR) assay of intracellular vaccinia virus in PC-3 cells (n=3). (A) Linearity 
of Ct (cycle threshold) from qPCR using different dosage of templet. (B) Time-dependent viral amplification in PC-3. MOI, multiplicity 
of infection.
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Figure 3. Results of qPCR quantification assay of intracellular 
vaccinia virus in PC-3 cells, and pH changes observed after 
treatment with/without ALDO alone, or ALDO with SPI in the 
presence or absence of EIPA. n=3 for each group, 
*  P<0.05. 
EIPA, 5-(N-ethyl-N-isopropyl) amiloride.
Fig. 1D indicates aldosterone (10 nM) does not affect cell growth 
significantly in cancer cell lines we tested while high dose of 
aldosterone (100 nM) may slightly inhibit cell proliferation in 
some cell lines. These results suggest no association of viral 
replication with aldosterone mediated cell growth. 
As vaccinia virus enters cell in an extracellular H
+ dependent 
fashion
7,13 and aldosterone can cause a change in cytosolic pH in 
specific cell lines,
14,15 we addressed the possibility that change in 
hydrogen gradient across the plasma membrane can be involved 
in stimulation of JX-594 amplification in this study. For this 
purpose, we developed an assay for JX-594 entry into plasma 
membrane (Fig. 2). In this assay, qPCR based quantification of 
JX-594 entry after its treatment into cultured cells showed 
linearity plot of Ct and treated viral doses of 1-0.01 MOI 
(Fig. 2A). JX-594 copy number was stable until 2 hours post 
treatment, but significant increase at 4 hour post JX-594 
treatment suggesting no viral replication at least for 2 hours post 
JX-594 treatment (Fig. 2B). Therefore we chose the condition of 
30 minutes treatment after administration of 1 MOI JX-594 to 
measure viral entry but not replication. Quality controlled qPCR 
assay for clinical samples
3 was used in this study. Fig. 3 shows 
that aldosterone slightly but not statistically increased viral entry. 
However, spirinolactone alone inhibited basal level of viral entry 
suggesting that basal MR activity may be involved in JX-594 
entry. Simultaneous treatment of aldosterone and spirinolactone 
inhibited aldosterone stimulated viral entry but not as much as 
spirinolactone alone suggesting competition between aldosterone 
and spirinolactone. Na
+/H
+ exchanger inhibitor, EIPA, signi-
ficantly decreased basal level of JX-594 entry but this was 
slightly recovered by aldosterone treatment. This suggests that 
competition between aldosterone and spirinolactone is present 
also in the presence of EIPA. Then, we measured intracellular pH 
after aldosterone treatment in PC-3 cell. Aldosterone stimulated 
intracellular alkalization which was blocked by EIPA. Simultaneous 
treatment of aldosterone and EIPA recovered EIPA mediated 
cytosolic acidification but not to as much as aldosterone alone 
mediated alkalization suggesting competition between aldosterone 
and EIPA. Spirinoractone treated with/without aldosterone 
showed no significant effect in pH level which possibly suggests 
study limitations in interpreting this assay (data not shown).
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DISCUSSION
Viral replication in oncolytic viral therapeutics is a double- 
edged sword. Efficient replication of oncolytic virus is essential 
for successful treatment. In contrast, in immune deficient 
patients, uncontrollable viral replication can cause serious clinical 
conditions. Therefore, pharmacological modulation of oncolytic 
virus replication may be the key to maximize the therapeutic 
window of oncolytic viruses.
Aldosterone level may be increased in terminal phase of tumor 
malignancy patients. Accordingly any cancer drug which potentially 
interacts with aldosterone should be used cautiously. As shown 
in Fig. 1B, treatment time of aldosterone may have different 
effect on vv replication suggesting aldosterone effect on a 
genomic level. This was further confirmed in Fig. 1C showing 
log scale increase of viral replication after 24 hrs and 48 hrs post 
infection. We speculate non-genomic level to be involved in 
aldosterone as well, and this can be seen in transient treatment of 
aldosterone affecting pH and virus entry (Fig. 3). Overall, the 
results of this study show that aldosterone can increase vaccinia 
virus entrance in vitro which may be responsible for increased 
viral amplification. The reason for minimum increase of viral 
entry by aldosterone determined by qPCR in this study (Fig. 3) 
may be due to technical limitations (qPCR after 30 minutes 
treatment at 4℃ to exclude the possibility of JX-594 replication 
step). Previous studies showed that extracellular acidity can 
affect vaccinia virus mobility
16 and acidic solution can stimulate 
vaccinia virus entrance into host cell.
7,13 In this study, 
aldosterone treatment stimulated JX-594 entrance possibly via 
intracellular alkalization. It was that aldosterone treatment could 
modify hydrogen conductance in variety of cells such as renal 
epithelia cells and smooth muscle cells.
17,18 After pretreatment of 
aldosterone in this study, alkalinized intracellular pH was 
reversed by JX-594 treatment suggesting the possibility of use of 
extracelluar H
+ as a driving force on viral entrance. 
It is possible that the H
+ gradient across the plasma membrane 
can affect vaccinia virus entrance depending on cell lines. 
Extracellular Hydrogen as a potential driving force for JX-594 
entry is interesting because the tumor microenvironment is 
accompanied with chronic inflammation which provide acidic 
environment
7,13 In addition to its inherent cancer tropism and 
genetic background vaccinia oncolytic virus, this may explain 
another factor for tumor specificity of JX-594.
In other aspect, vaccinia virus as a smallpox vaccination in 
human is being considered with the emergence of bioterrorism.
19 
However, post vaccination encephalitis was reported to be a 
serious safety concern for future vaccination
20. Therefore, as is 
described in “Introduction”, it is also interesting to note 
postvaccination encephalitis and cardiomyositis parallels with 
high level expression of MR in specific areas of the brain and 
cardiomyocytes. This study may provide the possibility of 
pharmacological modulation of fatal vaccinia virus amplification 
potentially minimizing postvaccination encephalitis and myo- 
pericardiomyositis. However, cytosolic pH involves many 
complexities which brought many study limitations and since 
our study did not include in vivo studies, further experiments are 
necessary to address the mechanisms involved. In conclusion, 
this study suggests potential pharmacological intervention in the 
replication of oncolytic vaccinia virus.
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